ZYLOXTB (02190) rose nearly 5% during the trading session. As of the time of writing, the stock was up 3.88%, trading at HK$26.26, with a turnover of HK$6.7268 million.

On January 16, ZYLOXTB announced that it had signed an agreement with German medical technology company Optimed Medizinische Instrumente GmbH, which specializes in minimally invasive vascular and urological interventions, to acquire its equity in phases and holds an option to purchase all remaining equity and corresponding interests in Optimed in the future.

This acquisition is set to become a significant milestone in the company's global expansion. By integrating Optimed's established R&D, manufacturing, and commercial platform in Europe, ZYLOXTB will further extend its footprint in the European and global markets, accelerating the international promotion and deployment of its innovative products.

Leveraging the synergistic effects between its manufacturing bases in China and Germany, the company will continue to enhance its global operational and delivery capabilities, providing high-quality and affordable innovative products and solutions to a broader patient base.

Optimed is a German medical technology enterprise focused on the R&D, production, and global sales of minimally invasive vascular and urological intervention medical devices. Its current sales and service network spans over 70 countries, and it maintains long-term, close collaborations with European clinicians and academic key opinion leaders.

In the field of peripheral venous treatment, several of Optimed's venous stent products enjoy wide market recognition and a strong brand reputation. The efficacy of its iliac vein stent, sinus-Venous, has been thoroughly validated in the STEVECO clinical trial.